Modulating the proliferative response to treat restenosis after vascular injury

Molecular and Translational Vascular Medicine

Volumn , Issue , 2012, Pages 227-248

  Andrés, Vicente ^a   Fuster, José Javier ^a   Silvestre Roig, Carlos ^a   Wessely, Rainer ^b  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b Department of Cardiology and Angiology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892967896     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-906-8_8     Document Type: Chapter

References (142)

1. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301(2):61-8.
2. Palmaz JC, Sibbitt RR, Reuter SR, et al. Expandable intraluminal graft: a preliminary study. Radiology. 1985;156(1):73-7.
3. Schatz RA, Palmaz JC, Tio FO, et al. Balloon-expandable intracoronary stents in the adult dog. Circulation. 1987;76(2):450-7.
4. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316(12):701-6.
5. Andrés V. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential. Cardiovasc Res. 2004;63(1):11-21.
6. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8(11):1249-56.
7. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103(2):192-5.
8. Rensing BJ, Vos J, Smits PC, et al. Coronary restenosis elimination with a sirolimus eluting stent:first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J. 2001;22(22):2125-30.
9. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006;354(5): 483-95.
10. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46(2):231-6.
11. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drugeluting coronary stents: a review of available cases from the research on adverse drug events and reports (RADAR) project. J Am Coll Cardiol. 2006;47(1):175-81.
12. Gonzalo N, Barlis P, Serruys PW, et al. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography. JACC Cardiovasc Interv. 2009;2(5):445-52.
13. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet. 2008;371(9630):2134-43.
14. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126-30.
15. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005;111(17):2257-73.
16. Vidal A, Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene. 2000; 247(1-2):1-15.
17. Bonauer A, Boon RA, Dimmeler S. Vascular microRNAs. Curr Drug Targets. 2010; 11:943-9.
18. Davis BN, Hilyard AC, Nguyen PH, et al. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem. 2009;284(6):3728-38.
19. Liu X, Cheng Y, Zhang S, et al. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res. 2009;104(4):476-87.
20. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J Am Coll Cardiol. 2004;44(7):1373-85.
21. Schwartz RS, Edelman ER, Carter A, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002;106(14):1867-73.
22. Virmani R, Kolodgie FD, Farb A, et al. Drug eluting stents: are human and animal studies comparable? Heart. 2003;89(2):133-8.
23. Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem. 2010;285(19):14071-7.
24. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21-35.
25. Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76(3):412-7.
26. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98(10):2277-83.
27. Wessely R, Blaich B, Belaiba RS, et al. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thromb Haemost. 2007;97(6):1003-12.
28. Luo Y, Marx SO, Kiyokawa H, et al. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol. 1996;16(12):6744-51.
29. Sun J, Marx SO, Chen HJ, et al. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation. 2001;103(24):2967-72.
30. Diez-Juan A, Andres V. Coordinate control of proliferation and migration by the p27Kip1/ cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells andfibroblasts. Circ Res. 2003;92(4):402-10.
31. Castro C, Diez-Juan A, Cortes MJ, et al. Distinct regulation of mitogen-activated protein kinases and p27Kip1 in smooth muscle cells from different vascular beds. A potential role in establishing regional phenotypic variance. J Biol Chem. 2003;278(7):4482-90.
32. Burke SE, Lubbers NL, Chen YW, et al. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol. 1999;33(6): 829-35.
33. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999; 99(16):2164-70.
34. Jahnke T, Schafer FK, Bolte H, et al. Short-term rapamycin for inhibition of neointima formation after balloon-mediated aortic injury in rats: is there a window of opportunity for systemic prophylaxis of restenosis? J Endovasc Ther. 2005;12(3):332-42.
35. Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slowrelease, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63(4): 617-24.
36. Carter AJ, Wei W, Gibson L, et al. Segmental vessel wall shear stress and neointimal formation after sirolimus-eluting stent implantation: physiological insights in a porcine coronary model. Cardiovasc Revasc Med. 2005;6(2):58-64.
37. Tepe G, Muschick P, Laule M, et al. Prevention of carotid artery restenosis after sirolimuscoated stent implantation in pigs. Stroke. 2006;37(2):492-4.
38. Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002;13(3):183-8.
39. Langeveld B, Roks AJ, Tio RA, et al. Rat abdominal aorta stenting: a new and reliable small animal model for in-stent restenosis. J Vasc Res. 2004;41(5):377-86.
40. Pires NM, van der Hoeven BL, de Vries MR, et al. Local perivascular delivery of antirestenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. Biomaterials. 2005;26(26):5386-94.
41. Pires NM, Eefting D, de Vries MR, et al. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart. 2007;93(8):922-7.
42. Barilli A, Visigalli R, Sala R, et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res. 2008;78(3):563-71.
43. Hayashi S, Yamamoto A, You F, et al. The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009;175(5):2226-34.
44. Singh R, Cuervo AM. Autophagy in the cellular energetic balance. Cell Metab. 2011; 13(5):495-504.
45. Frey D, Billinger M, Meier P, et al. Endothelialization of sirolimus-eluting stents with slow and extended drug release in the porcine overstretch model. J Invasive Cardiol. 2008; 20(12):631-4.
46. Imanishi T, Kobayashi K, Kuki S, et al. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis. 2006;189(2):288-96.
47. Nuhrenberg TG, Voisard R, Fahlisch F, et al. Rapamycin attenuates vascular wall in fl ammation and progenitor cell promoters after angioplasty. FASEB J. 2005;19(2):246-8.
48. Andrés V, Castro C, Campistol JM. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. Nephrol Dial Transplant. 2006;21 Suppl 3:iii14-7.
49. Carter AJ, Brodeur A, Collingwood R, et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interv. 2006;68(1):97-103.
50. Garcia-Touchard A, Burke SE, Toner JL, et al. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J. 2006;27(8):988-93.
51. Tada N, Virmani R, Grant G, et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced in fl ammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv. 2010;3(2):174-83.
52. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003;3(3):193-203.
53. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 1995;95(4):1869-76.
54. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997; 96(2):636-45.
55. Wiskirchen J, Schober W, Schart N, et al. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol. 2004;39(9):565-71.
56. Kim DW, Kwon JS, Kim YG, et al. Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation. 2004;109(12):1558-63.
57. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol. 2000;35(7):1969-76.
58. Wilson GJ, Polovick JE, Huibregtse BA, et al. Overlapping paclitaxel-eluting stents: longterm effects in a porcine coronary artery model. Cardiovasc Res. 2007;76(2):361-72.
59. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103(18): 2289-95.
60. Wessely R, Schömig A, Kastrati A. Sirolimus and paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol. 2006;47(4):708-14.
61. Finkelstein A, McClean D, Kar S, et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation. 2003;107(5):777-84.
62. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003;42(8):1415-20.
63. Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110(7):810-4.
64. Epstein FH, Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801-11.
65. Xing D, Nozell S, Chen Y-F, et al. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol. 2009;29(3):289-95.
66. Geraldes P, Sirois MG, Bernatchez PN, et al. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: Role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol. 2002;22(10):1585-90.
67. Geraldes P, Sirois MG, Tanguay J-F. Specific contribution of estrogen receptors on mitogenactivated protein kinase pathways and vascular cell activation. Circ Res. 2003;93(5): 399-405.
68. Cheng B, Song J, Zou Y, et al. Responses of vascular smooth muscle cells to estrogen are dependent on balance between ERK and p38 MAPK pathway activities. Int J Cardiol. 2009; 134(3):356-65.
69. Kappert K, Caglayan E, Huntgeburth M, et al. 17Beta-estradiol attenuates PDGF signaling in vascular smooth muscle cells at the postreceptor level. Am J Physiol Heart Circ Physiol. 2006;290(2):H538-46.
70. Krasinski K, Spyridopoulos I, Asahara T, et al. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation. 1997;95(7):1768-72.
71. Toutain CE, Filipe C, Billon A, et al. Estrogen receptor alpha expression in both endothelium and hematopoietic cells is required for the accelerative effect of estradiol on reendothelialization. Arterioscler Thromb Vasc Biol. 2009;29(10):1543-50.
72. Filipe C, Lam Shang Leen L, Brouchet L, et al. Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium. Am J Physiol Heart Circ Physiol. 2008;294(6):H2822-30.
73. Iwakura A, Luedemann C, Shastry S, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003;108(25):3115-21.
74. Chen S-J, Li H, Durand J, et al. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation. 1996;93(3):577-84.
75. Iafrati MD, Karas RH, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor-deficient mice. Nat Med. 1997;3(5):545-8.
76. Sullivan Jr TR, Karas RH, Aronovitz M, et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest. 1995;96(5):2482.
77. Levine RL, Chen S-J, Durand J, et al. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 1996;94(9):2221-7.
78. Oparil S, Levine RL, Chen S-J, et al. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation. 1997;95(5):1301-7.
79. Bakir S, Mori T, Durand J, et al. Estrogen-induced vasoprotection is estrogen receptor dependent: evidence from the balloon-injured rat carotid artery model. Circulation. 2000;101(20): 2342-4.
80. Mori T, Durand J, Chen Y-F, et al. Effects of short-term estrogen treatment on the neointimal response to balloon injury of rat carotid artery. Am J Cardiol. 2000;85(10):1276-9.
81. Hanke H, Hanke S, Bruck B, et al. Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis. 1996;121(1):129-38.
82. Foegh ML, Asotra S, Howell MH, et al. Estradiol inhibition of arterial neointimal hyperplasia after balloon injury. J Vasc Surg. 1994;19(4):722-6.
83. White CR, Shelton J, Chen S-J, et al. Estrogen restores endothelial cell function in an experimental model of vascular injury. Circulation. 1997;96(5):1624-30.
84. Chandrasekar B, Tanguay J-F. Local delivery of 17-beta-estradiol decreases neointimal hyperplasia after coronary angioplasty in a porcine model. J Am Coll Cardiol. 2000;36(6): 1972-8.
85. New G, Moses JW, Roubin GS, et al. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Interv. 2002;57(2):266-71.
86. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37-44.
87. Jaschke B, Michaelis C, Milz S, et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res. 2005;68(3):483-92.
88. Ruef J, Meshel AS, Hu Z, et al. Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation in vivo after carotid injury in the rat. Circulation. 1999;100(6): 659-65.
89. Jaschke B, Milz S, Vogeser M, et al. Local cyclin-dependent kinase inhibition by fl avopiridol inhibits coronary artery smooth muscle cell proliferation and migration: implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. FASEB J. 2004;11:1285-7.
90. Sung C-P, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol. 1993;21(2):221-7.
91. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A. 1993;90(13):6189-93.
92. Kim W, Jeong MH, Cha KS, et al. Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. Circ J. 2005;69(1):101-6.
93. Miyauchi K, Aikawa M, Tani T, et al. Effect of probucol on smooth muscle cell proliferation and dedifferentiation after vascular injury in rabbits: possible role of PDGF. Cardiovasc Drugs Ther. 1998;12(3):251-60.
94. Lau AK, Leichtweis SB, Hume P, et al. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation. 2003;107(15):2031-6.
95. Tanous D, Bräsen JH, Choy K, et al. Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization. Atherosclerosis. 2006;189(2):342-9.
96. Jackson CL, Pettersson KS. Effects of probucol on rat carotid artery responses to balloon catheter injury. Atherosclerosis. 2001;154(2):407-14.
97. Yokoyama T, Miyauchi K, Kurata T, et al. Effect of probucol on neointimal thickening in a stent porcine restenosis model. Jpn Heart J. 2004;45(2):305-13.
98. Takahashi S, Oida K, Fujiwara R, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992;20(6):900-6.
99. Hayashi S, Morishita R, Matsushita H, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension. 2000;35(1):237-43.
100. Aoki M, Morishita R, Hayashi S, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia. 2001;44(8):1034-42.
101. Tsuchikane E, Suzuki T, Katoh O. Examination of anti-intima hyperplastic effect on cilostazol- eluting stent in a porcine model. J Invasive Cardiol. 2007;19(3):109-12.
102. Lee C-S, Kwon Y-W, Yang H-M, et al. New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. Arterioscler Thromb Vasc Biol. 2009;29(4):472-9.
103. Phillips JW, Barringhaus KG, Sanders JM, et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation. 2003;108(16):1994-9.
104. Desouza CV, Murthy SN, Diez J, et al. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J Cardiovasc Pharmacol Ther. 2003;8(4):297-305.
105. Alessi A, França Neto O, Brofman P, et al. Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: assessment of neointimal formation. Thromb J. 2008; 6(1):12.
106. Joner M, Farb A, Cheng Q, et al. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol. 2007;27(1):182-9.
107. Kasai T, Miyauchi K, Yokoyama T, et al. Pioglitazone attenuates neointimal thickening via suppression of the early in fl ammatory response in a porcine coronary after stenting. Atherosclerosis. 2008;197(2):612-9.
108. Miyazawa K, Kikuchi S, Fukuyama J, et al. Inhibition of PDGF- and TGF-[beta]1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis. 1995;118(2):213-21.
109. Miyazawa K, Hamano S, Ujiie A. Antiproliferative and c-myc mRNA suppressive effect of tranilast on newborn human vascular smooth muscle cells in culture. Br J Pharmacol. 1996;118(4):915.
110. Watanabe S, Matsuda A, Suzuki Y, et al. Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors. Br J Pharmacol. 2000;130(2):307-14.
111. Tanaka K, Honda M, Kuramochi T, et al. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. 1994;107(2):179-85.
112. Sata M, Takahashi A, Tanaka K, et al. Mouse genetic evidence that tranilast reduces smooth muscle cell hyperplasia via a p21(WAF1)-dependent pathway. Arterioscler Thromb Vasc Biol. 2002;22(8):1305-9.
113. Fukuyama J, Ichikawa K, Miyazawa K, et al. Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Jpn J Pharmacol. 1996; 70(4):321.
114. Fukuyama J, Ichikawa K, Hamano S, et al. Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet. Eur J Pharmacol. 1996;318(2-3):327-32.
115. Miyazawa N, Umemura K, Kondo K, et al. Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat. J Cardiovasc Pharmacol. 1997;30(2):157-62.
116. Kikuchi S, Umemura K, Kondo K, et al. Tranilast suppresses intimal hyperplasia after photochemically induced endothelial injury in the rat. Eur J Pharmacol. 1996;295(2-3): 221-7.
117. Ward MR, Agrotis A, Kanellakis P, et al. Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol. 2002;22(6):940-8.
118. Ishiwata S, Verheye S, Robinson KA, et al. Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation. J Am Coll Cardiol. 2000;35(5):1331-7.
119. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009; 360(10):961-72.
120. Kim YH, Park SW, Lee CW, et al. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. Catheter Cardiovasc Interv. 2006;67(2):181-7.
121. Colmenarez HJ, Escaned J, Fernandez C, et al. Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(17):1854-66.
122. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355(11):1093-104.
123. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004;292(22):2727-34.
124. Holmes Jr DR, Teirstein PS, Satler L, et al. 3-Year follow-up of the SISR (sirolimus-eluting stents versus vascular brachytherapy for in-stent restenosis) trial. JACC Cardiovasc Interv. 2008;1(4):439-48.
125. Latib A, Ferri L, Ielasi A, et al. Comparison of the long-term safety and efficacy of drugeluting and bare-metal stent implantation in saphenous vein grafts. Circ Cardiovasc Interv. 2010;3(3):249-56.
126. Stenestrand U, James SK, Lindback J, et al. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2010;31(2):177-86.
127. Sukhija R, Aronow WS, Palaniswamy C, et al. Major adverse cardiac events in patients with moderate to severe renal insufficiency treated withfirst-generation drug-eluting stents. Am J Cardiol. 2010;105(3):293-6.
128. Lee MS, Kobashigawa J, Tobis J. Comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy. JACC Cardiovasc Interv. 2008;1(6):710-5.
129. Morice MC, Bestehorn HP, Carrie D, et al. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention. 2006;2(1):45-52.
130. Verheye S, Agostoni P, Dawkins KD, et al. The GENESIS (randomized, multicenter study of the pimecrolimus-eluting and pimecrolimus/paclitaxel-eluting coronary stent system in patients with de novo lesions of the native coronary arteries) trial. JACC Cardiovasc Interv. 2009;2(3):205-14.
131. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23): 1773-80.
132. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008;337:a1331.
133. Cassese S, Piccolo R, Galasso G, et al. Twelve-month clinical outcomes of everolimuseluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials. Int J Cardiol. 2011;150:84-9.
134. Adriaenssens T, Mehilli J, Wessely R, et al. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol. 2007;49(12):1265-71.
135. Byrne RA, Mehilli J, Iijima R, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J. 2009;30(8):923-31.
136. Grines CL, Bonow RO, Casey Jr DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulations. 2007;115(6):813-8.
137. Wessely R. New drug-eluting stent concepts. Nat Rev. 2010;7(4):194-203.
138. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372(9644):1163-73.
139. Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol. 2005;25(4):748-53.
140. Clapper JD, Pearce ME, Guymon CA, et al. Biotinylated biodegradable nanotemplated hydrogel networks for cell interactive applications. Biomacromolecules. 2008;9(4):1188-94.
141. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007;369(9576):1869-75.
142. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616):899-907.